# Kishiwada City Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/kishiwada-city-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 13.5 |
| Citations | 33,341 |
| City | Osaka |
| Country | JP |
| Description | Kishiwada City Hospital is a research organisation in Osaka, JP. OpenAlex records 1,033 works and 33,341 citations for it. 273 researchers list it as their most recent affiliation. |
| Homepage | http://www.kishiwada-hospital.com/ |
| OpenAlex ID | https://openalex.org/I4210108658 |
| Researchers | 273 |
| ROR ID | https://ror.org/01jhgy173 |
| Type | healthcare |
| Works | 1,033 |

## University papers

Showing 12 of 21.

- [Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)](https://scholariq.org/papers/safety-and-efficacy-of-nivolumab-in-combination-with-s-1-capecitabine-plus/)
- [An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC](https://scholariq.org/papers/an-her3-targeting-antibody-drug-conjugate-incorporating-a-dna-topoisomerase-i/)
- [Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors](https://scholariq.org/papers/clinical-application-of-the-foundationone-cdx-assay-to-therapeutic-decision/)
- [Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer](https://scholariq.org/papers/targeting-of-the-her2-her3-signaling-axis-overcomes-ligand-mediated-resistance/)
- [HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer](https://scholariq.org/papers/her2-genomic-amplification-in-circulating-tumor-dna-from-patients-with-cetuximab/)
- [Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification](https://scholariq.org/papers/roles-of-bim-induction-and-survivin-downregulation-in-lapatinib-induced/)
- [Anthocyanin production in suspension cultures of high-producing cells of Euphorbia millii.](https://scholariq.org/papers/anthocyanin-production-in-suspension-cultures-of-high-producing-cells-of/)
- [Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer](https://scholariq.org/papers/mutational-activation-of-the-epidermal-growth-factor-receptor-down-regulates/)
- [Incidence of opioid‐induced constipation in Japanese patients with cancer pain: A prospective observational cohort study](https://scholariq.org/papers/incidence-of-opioid-induced-constipation-in-japanese-patients-with-cancer-pain-a/)
- [High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin](https://scholariq.org/papers/high-dose-dexamethasone-plus-antihistamine-prevents-colorectal-cancer-patients/)
- [Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib](https://scholariq.org/papers/progression-free-and-overall-survival-of-patients-with-alk-rearrangement/)
- [Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal](https://scholariq.org/papers/chronic-nicotine-exposure-mediates-resistance-to-egfr-tki-in-egfr-mutated-lung/)

## University researchers

- [Satomi Watanabe](https://scholariq.org/researchers/satomi-watanabe/)
- [Soichi Fumita](https://scholariq.org/researchers/soichi-fumita/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Shoulder Injury and Treatment](https://scholariq.org/topics/shoulder-injury-and-treatment/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.